Arcview Co-Hosts Hong Kong’s First Ever Cannabis Investor Symposium

CHINA: Hong Kong’s first-ever Cannabis Investor Symposium will take place on November 1, 2018 at the W Hotel. The one-day gathering is hosted by The Arcview Group, CannaTech and URI Capital Management.

The Cannabis industry is the fastest growing market in the world and the legal cannabis business is expected to generate $57 billion globally by 2027 as countries throughout the world continue to legalize its use and demand continues to grow exponentially.

The Hong Kong Symposium will focus on the global investment opportunity but is specially curated toward the Asian market.

The most powerful cannabis business leaders and investment experts from around the world will gather to discuss the burgeoning industry.

Keynote and panel discussions will cover Cannabis and China, The Cannabis Value Chain, Market Insights: Australasia, Public and Private Investment Opportunities, Risks and Regulations, World Cannabis Policy and more.

The event is designed for those looking to gain insight into investment opportunities in the global cannabis market, family offices, money managers, venture capital firms, private equity funds, and institutional investors.

Troy Dayton, CEO of The Arcview Group adds: “The worldwide cannabis market is exploding, and Asian investors are increasingly paying attention. Up until now, pioneering Asian investors have only been able to simply read about this fascinating industry. Not anymore. We are bringing the cannabis industry to them.”

Saul Kaye, CEO of CannaTech and iCAN said of the symposium, “The time has come for serious Asian investors to enter the market. The Hong Kong event will take place days after CannaTech Sydney, Australia’s first Medical Cannabis Summit. The region’s attitude is evolving quickly, particularly with respect to Medical Cannabis and the industry needs to learn more. Currently dominated by American and Canadian investors, the time is right for the Asian investment community to join this industry. We are thrilled to partner with Arcview and URI Fund on this important event.”

Uri Capital Management added: “Cannabis usage as a medicinal plant dates back in Chinese history for thousands of years. Medicinal cannabis research is rapidly progressing, and we need to redefine our attitude towards cannabis and hemp. Asia, more specifically China, is poised to leverage its unique advantages in Hemp and agriculture to become a dominant global leader. URI is proud to become the first Chinese financial conglomerate to focus on the Asian cannabis industry and will leverage the firm’s world class research and investment resources to lead the way.”

For more information about the Hong Kong Cannabis Symposium, click here.





Canadian Producer Aphria Comments On News Of Pesticide Use; Reaffirms Commitment To Quality And Safety

CANADA: Despite most Licensed Producers taking great care to provide safe and effective products, there are still reports surfacing regarding the presence of harmful pesticides in regulated medical cannabis. “We support the use of independent evaluations and testing of medical cannabis as a necessary measure to protect the safety of Canadians,” said Vic Neufeld, Chief Executive Officer of Aphria Inc.

Patients rely on a safe and high quality product to meet their medical needs and it is critically important that all products sold through the ACMPR adhere to the strict guidelines established by Health Canada to ensure that their needs are met.

“Aphria has always held itself to the highest standards when it comes to the production and cultivation of medical cannabis. This commitment stems from over 40 years of experience balancing the science, experience and economics of growing high quality and consistent products for commercial scale sales,” said Cole Cacciavillani, Co-Founder.

Aphria relies on a strict Quality Management Program that continuously tests for pesticides and monitors all suppliers to ensure that any products used exceed the minimum standards set to comply with Health Canada’s regulations.

China’s Marijuana Surprise

CHINA:  An economic stir is happening in China, but it’s in an industry you might not expect. With more than half of the 600 relevant patents filed with the World Intellectual Property Office now owned by Chinese companies, the country is well positioned to dominate the global cannabis market. Which is very surprising for a nation where drug trafficking is still punishable by death and mere possession of the substance can result in a lengthy spell behind bars.

Chinese investment in the cannabis market could not be more perfectly timed, as countries like the U.S. and Uruguay begin to experiment with decriminalization. Medical marijuana research has surged over the last decade as medicine and finance have coalesced to legitimize the business of cannabis. The fervor for the war on drugs that has for decades driven the policies and public opinion on marijuana decriminalization is slowly fading. In the U.S., where cannabis is nowlegal in four states, the rhetoric is moving away from issues like crime and security, to more progressive discussions on race, mass incarceration, and personal freedom.

Meanwhile, there is another emerging dimension: Western medicine is beginning to take more seriously the tradition and techniques of alternative medicine popularized by China. Part of this tradition is cannabis, which has been used to treat illnesses ranging from depression to constipation.

China is uniquely poised to take advantage of cannabis production because of its strong patent control and the fact that its production of pharmaceuticals is surpassing the West. As Dr. Luc Dechesne states: “Because cannabis in Western medicine is becoming accepted, the predominance of Chinese patents suggests that pharmaceutical sciences are evolving quickly in China, outpacing Western capabilities.” China is already one of the leading exporters of hemp and is well positioned to benefit from any future boom in cannabis.